http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2012203623-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f69bebf6ea8f1b03e47d5ffade9fa037 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2012-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb2ea492b17255a760bfc4172659962c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b02cf313ab4f595625193a6032e9ef2 |
| publicationDate | 2012-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2012203623-A1 |
| titleOfInvention | Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| abstract | AEROSOLIZED FOSFOMYCIN/AMINOGLYCOSIDE COMBINATION FOR THE TREATMENT OF BACTERIAL RESPIRATORY INFECTIONS Abstract Aerosol formulations are described for the prevention and treatment of infection caused by susceptible bacteria in the respiratory tract of a patient. The formulation comprises from about I mg to about 300 mg of fosfomycin and about I mg to about 300 mg of an aminoglycoside selected from the group of gentamicin, kanamycin B, amikacin, arbekacin, dibekacin, streptomycin, neomycin, and netilmicin the formulation having a particle size distribution between 1 and 5 Pm and being adapted for administration by aerosolization or by dry powder inhaler. Also described are methods for the prevention and treatment of infections of the respiratory tract caused by bacteria comprising administering to a patient in need of such treatment such formulations. |
| priorityDate | 2004-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 99.